Zevra Therapeutics(ZVRA) - 2025 Q4 - Earnings Call Transcript

Financial Performance - In Q4 2025, total net revenue was $34.1 million, including $26.4 million from MIPLYFFA sales, $400,000 from OLPRUVA, $5.6 million from global EAP reimbursements, and $1.8 million from royalties under the AZSTARYS license [22][23] - For the full year 2025, net revenue reached $106.5 million, with $87.4 million from MIPLYFFA sales, $800,000 from OLPRUVA, $13 million from global EAP reimbursements, and $5 million from royalties [24] - Operating expenses for Q4 were $23 million, a decrease of $1.5 million year-over-year, while full-year operating expenses were $90.4 million, down $6.6 million from 2024 [22][24] - Net income for Q4 was $12.2 million, compared to a net loss of $35.7 million in Q4 2024, and full-year net income was $83.2 million, compared to a net loss of $105.5 million in 2024 [23][24] Business Line Performance - MIPLYFFA generated $87.4 million in revenue for the full year 2025, with strong commercial performance reflected in 52 prescription enrollment forms received in the first year of commercialization [5][6] - In Q4, 24 new prescription enrollment forms were received, contributing to a total of 161 enrollments since launch [6][14] - The company is expanding access to MIPLYFFA through a global expanded access program, with 113 patients enrolled by the end of 2025 [8] Market Data - The estimated U.S. prevalence of Niemann-Pick disease type C (NPC) is approximately 900 individuals, with 300-350 currently diagnosed [7] - In Europe, NPC prevalence is estimated at around 1,100 individuals, with the current EAP supporting nearly 10% of this population [9] - Diagnosis rates in Europe are higher due to the approval of miglustat, leading to stronger physician awareness and higher patient identification [10] Company Strategy and Industry Competition - The company aims to redefine therapies for rare diseases, focusing on patient-centricity, integrity, accountability, innovation, and courage [5] - MIPLYFFA has exclusivity in the U.S. through 2031 under the Orphan Drug Designation, and the company is pursuing a patent term extension [7] - The company is also advancing celiprolol for the treatment of vascular Ehlers-Danlos syndrome, with ongoing Phase III studies [10][11] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MIPLYFFA, driven by both previously diagnosed and newly diagnosed patients [15][16] - The company is focused on expanding access and strengthening relationships with key opinion leaders to maximize commercial impact [10] - Management highlighted the importance of ongoing education and awareness campaigns to facilitate early diagnosis and treatment [16][18] Other Important Information - The company moved its headquarters to Boston to enhance collaboration and access to specialized talent [12][13] - The new CFO, Justin Renz, officially started on the call date and will support the company's long-term value creation [4][28] Q&A Session Summary Question: Can you provide details on the split of new diagnoses versus previously identified patients? - Management noted that there has been meaningful growth in newly diagnosed patients, attributed to clinical data strength and disease awareness campaigns [33][34] Question: What is the expected timeline for diagnosis confirmation? - Management indicated that the timeline for diagnosis can vary significantly due to the nature of rare diseases, but efforts are being made to streamline the process [37][40] Question: Can you discuss persistency rates for patients on therapy? - Management stated that it is too early to provide meaningful data on persistency but expressed encouragement from refill rates observed [45][46] Question: How is the initial experience with the Uniphar collaboration? - Management expressed satisfaction with the collaboration, noting that it has facilitated rapid product delivery to patients [47][48] Question: What is the expected growth of EAP revenue? - Management clarified that EAP revenue is based on individual patient shipments and will have variability quarter-over-quarter [54][55] Question: How is the gross to net evolving in the U.S.? - Management noted that gross to net has evolved and is dynamic, making it difficult to provide specific guidance [58] Question: What is the average age of patients on MIPLYFFA? - Management indicated that approximately half of MIPLYFFA patients are adults, reflecting the patient mix seen in the expanded access program [64][66] Question: What are the next steps for the EMA application? - Management confirmed readiness to respond to the EMA's questions and emphasized the robustness of the data package submitted [69]